<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="570452" id="root" date="1997-05-08" xml:lang="en">
<title>ISRAEL: Teva Q1 earnings per ADR $0.51.</title>
<headline>Teva Q1 earnings per ADR $0.51.</headline>
<dateline>TEL AVIV 1997-05-08</dateline>
<text>
<p>Teva Pharmaceutical Industries Ltd</p>
<p>		    (in thousands of dollars except per ADR data)</p>
<p>			   Q1 97	Q1 96</p>
<p>Sales		    267,578    220,085</p>
<p>Operating Income	45,412     28,024</p>
<p>Net Income		31,471     18,688</p>
<p>Earnings per ADR	 $0.51	$0.30</p>
<p>Weighted average  number of ADRs	 62,285     61,825</p>
<p>(in thousands)  </p>
<p>Teva, Israel's largest drug company, declared a regular first interim cash dividend for 1997 of 0.30 shekels ($0.09) per ADR to be paid on June 12.</p>
<p>Teva said the 1997 and 1996 results reflected the acquisition of Biocraft Laboratories Inc in May 1996. The 1996 comparative figures do not include the results of APS/Berk which was acquired in July 1996.</p>
<p>Sales outside of Israel represented 71 percent of total revenues in the first quarter of 1997. North America remains Teva's largest market, representing close to half its revenues.</p>
<p>&quot;The company's ability to increase its sales level in the American market, continuing price erosion not withstanding, has been attributable to the introduction of a number of new products,&quot; Teva said in a statement.</p>
<p>Since the beginning of the year the company has received six generic approvals in the United States.</p>
<p>European sales for the quarter rose to $47 million from $35 million, accounting for 18 percent of total sales. This increase was primarily attributable to the acquisition of APS/Berk in the United Kingdom.</p>
<p>Gross profit margins improved to 40.7 percent from 36.2 percent.</p>
<p>Gross research and development expenses fell 11 percent to $17 million.</p>
<p>-Tel Aviv newsroom, 972-3-537-2211</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="ISRAEL">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-08"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-08"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-08"/>
  </code>
  <code code="C152">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-08"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-05-08"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-05-08"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-05-08"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="TEL AVIV"/>
<dc element="dc.creator.location.country.name" value="ISRAEL"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
